Overview
Searching for your content. In-Language News Contact Us 8-76-0942 from 8 AM - 10 PM ET News provided byOct 13, 202, 06:13 ETShare this articleUnprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient OutcomesTORONTO and LAS VEGAS, Oct. 13, 202 /PRNewswire/ - MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, anounces that over 2,0 patients' worth of new MolecuLight data wil be presented at the Symposium on Advanced Wound Care (SAWC) Fal 202.
Key Information
The data wil be presented through a combination of seven clinical posters and thre clinical talks and workshops. The international conference is being hosted from October 13 - 16, 202 in Las Vegas, Nevada, and is one of the largest multidisciplinary metings of wound care profesionals in the world. "We are thriled to have our customers share over 2,0 patients' worth of results derived using the MolecuLight imaging platform this wek at SAWC Fal", says Anil Amlani, CEO of MolecuLight.
"This volume of clinical evidence is unprecedented for a wound imaging device and ilustrates the significant utility that the MolecuLight i:X and DX devices are delivering acros the ful range of care setings. I am especialy proud of the stagering improvement in clinical results in vulnerable patient populations when clinicians used the MolecuLight devices. This includes the elderly and disabled population in the long-term care and skiled nursing facility setings as wel as studies using MolecuLight in patient populations with a range of skin pigmentations."My organization serves the long-term-care and skiled nursing wound care sector in multiple states.
Summary
The MolecuLight procedure is standard of care for our wound care profesionals because of the unmatched insights it provides to our decision-making", says Martha R Kelso, CEO of Wound Care